Projects
This section presents pharmaceutical projects that are announced from time-to-time around the world.
Sherlock Biosciences to Open New Bio manufacturing Facility in UK
Sherlock Biosciences plans to open a new biomanufacturing facility located outside of Cambridge, UK
GeneFab Constructs New Manufacturing Facility in California, USA
GeneFab plans to construct a stateoftheart cGMP facility in California, USA, dedicated to the diverse spectrum of genetic medicines
Becton Dickinson Unveils US$36 million (€34 million) R & D Centre in Dublin, Ireland
BD expands operations with US$43 million 4 million RD Centre in Dublin and US$32 million 30 million investment in Enniscorthy manufacturing plant in Ireland
Catalent Expands its Shiga Site
Catalent expands the services and capabilities to support clinical supply demand for cell and gene therapy development in Shiga, Japan
Resilience and Lifera Plan for New Manufacturing Facility in Riyadh, Saudi Arabia
Resilience and Lifera plan for new biopharma manufacturing capacity in Riyadh, Saudi Arabia
AGC Biologics Expands Cell Suites in Longmont, USA
AGC Biologics plans a expansion, set to introduce three cuttingedge Grade B cell therapy suites within its Longmont facility in USA
EUROAPI Plans to Invest US$50 miilion (€50 million) to Open New Production Plant in Europe
The upcoming production plant in Budapest is set to be a pioneering facility equipped with advanced features to promote sustainability and operational efficiency
Cellares to Construct New Smart Factory in New Jersey, USA
Cellares plans to construct the first commercialscale smart factory in New Jersey, USA
McCord Development Invests US$30 million to Open BioHub in Texas, USA
McCord Development makes a investment of US$30 million to significantly expand its biomanufacturing capabilities with the establishment of BioHub Two
Astellas Pharma Set to Unveil State-of-the-Art Life Sciences Facility in Massachusetts, USA
Astellas Pharma opens a new stateoftheart life sciences facility to expand its RD footprint in order to accelerate innovation and deliver VALUE to patients
